ADAG

Adagene Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

Current Price

—

Profile

Valuation (TTM)

Market Cap—

P/E—

EV—

P/B—

Shares Out—

P/Sales—

Revenue—

EV/EBITDA—

Adagene Inc (ADAG) Valuation

ADAG Valuation Metrics

FCF—

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Fair Value Models

Graham Number, PEG-based, and Earnings-based models

View Fair Value →

ADAG Valuation & Fair Value Analysis

Adagene Inc (ADAG) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Adagene Inc's intrinsic value.